公开(公告)号：US09573903B2

公开(公告)日：2017-02-21

申请号：US15055197

申请日：2016-02-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Yamamoto ,  Junya Shirai ,  Tsuneo Oda ,  Mitsunori Kono ,  Atsuko Ochida ,  Takashi Imada ,  Hidekazu Tokuhara ,  Yoshihide Tomata ,  Naoki Ishii ,  Michiko Tawada ,  Yoshiyuki Fukase ,  Tomoya Yukawa ,  Shoji Fukumoto

IPC: C07D471/04 ,  C07D215/00 ,  C07D217/26 ,  C07F7/08 ,  C07D491/048 ,  C07D491/056 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/4741 ,  C07D217/14 ,  C07D491/14

CPC classification number: C07D217/26 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/4741 ,  C07D217/14 ,  C07D471/04 ,  C07D491/048 ,  C07D491/056 ,  C07D491/14 ,  C07F7/0812

Abstract: The present invention provides a heterocyclic compound having a RORγt inhibitory action.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.

Abstract translation: 本发明提供具有RORγt抑制作用的杂环化合物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义。 或其盐。

公开(公告)号：US09550756B2

公开(公告)日：2017-01-24

申请号：US14517313

申请日：2014-10-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko Taniguchi ,  Jun Kunitomo ,  Masato Yoshikawa ,  Makoto Fushimi

IPC: A61K31/501 ,  C07D403/04 ,  C07D403/14 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  A61K9/20

CPC classification number: C07D403/04 ,  A61K9/2059 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on.A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症等的药物。 式（I 0）的化合物：其中R 1表示取代基，R 2表示氢原子或取代基，R 3表示氢原子或取代基，环A表示可被取代的芳香环， 环B表示可被取代的5元杂芳环或其盐。

公开(公告)号：US20170008885A1

公开(公告)日：2017-01-12

申请号：US15103900

申请日：2014-12-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Summon KOUL ,  Suresh KURHADE ,  Sandeep BHOSALE ,  Keshav NAIK ,  Videsh SALUNKHE ,  Yogesh MUNOT ,  Debnath BHUNIYA

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Abstract translation: 本发明提供具有TLR7，TLR9，TLR7 / 8，TLR7 / 9或TLR7 / 8/9抑制作用的杂环化合物，其可用作预防或治疗自身免疫性疾病，炎性疾病等的药剂， 特别是系统性红斑狼疮，干燥综合征，类风湿性关节炎，牛皮癣，炎症性肠病等。 本发明是由式（1）表示的化合物：其中每个符号如说明书中所述或其盐。

公开(公告)号：US20160355494A1

公开(公告)日：2016-12-08

申请号：US15117538

申请日：2015-02-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Minoru SASAKI ,  Keiko KAKEGAWA ,  Fumiaki KIKUCHI ,  Zenichi IKEDA ,  Yoichi NISHIKAWA

IPC: C07D307/81

CPC classification number: C07D307/81

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

公开(公告)号：US09505772B2

公开(公告)日：2016-11-29

申请号：US14399396

申请日：2013-05-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shizuo Kasai ,  Hideyuki Igawa ,  Masashi Takahashi ,  Asato Kina

IPC: A61K31/50 ,  C07D491/048

CPC classification number: C07D491/048

Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

公开(公告)号：US09499516B2

公开(公告)日：2016-11-22

申请号：US15013625

申请日：2016-02-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D403/10 ,  C07D405/14 ,  C07D403/04 ,  C07D401/10 ,  C07D401/14 ,  C07D401/06 ,  C07D405/04

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09487511B2

公开(公告)日：2016-11-08

申请号：US14682695

申请日：2015-04-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu Matsumoto ,  Yasushi Hattori ,  Masashi Toyofuku ,  Shinji Morimoto ,  Masaki Daini ,  Takuto Kojima ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D333/40 ,  C07D333/38 ,  C07D407/12 ,  C07D409/12 ,  C07D417/14 ,  C07D417/12 ,  C07D307/79 ,  C07D213/82 ,  C07D413/14 ,  C07D231/14 ,  C07D285/08 ,  C07D285/135

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合征，歌舞伎综合征，脆性X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经变性疾病（如阿尔茨海默氏病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：US20160311811A1

公开(公告)日：2016-10-27

申请号：US15137161

申请日：2016-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato YOSHIDA ,  Kazuaki TAKAMI ,  Yusuke TOMINARI ,  Zenyu SHIOKAWA ,  Akito SHIBUYA ,  Yusuke SASAKI ,  Tony GIBSON ,  Terufumi TAKAGI

IPC: C07D413/14 ,  C07D401/14 ,  C07D403/14 ,  C07D403/04 ,  C07D495/04 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D409/14 ,  C07D471/10 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US09475816B2

公开(公告)日：2016-10-25

申请号：US14426369

申请日：2013-09-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Mingnam Tang

IPC: C07D487/04 ,  C07D519/00 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/437 ,  A61K31/496 ,  C07D487/14 ,  A61K31/4162 ,  A61K31/506

CPC classification number: C07D487/04 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  C07D487/14 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

公开(公告)号：US09464060B2

公开(公告)日：2016-10-11

申请号：US14463780

申请日：2014-08-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： William Buffham ,  Hannah Canning ,  Richard Davenport ,  William Farnaby ,  Stephen Mack ,  Alka Parmar ,  Susanne Wright

IPC: C07D239/34 ,  C07D213/78 ,  C07D213/81 ,  C07C235/52 ,  C07C235/46

CPC classification number: C07D239/34 ,  A61K31/195 ,  A61K31/277 ,  A61K31/44 ,  A61K31/505 ,  C07C235/44 ,  C07C235/46 ,  C07C235/52 ,  C07C255/54 ,  C07C2601/02 ,  C07C2601/04 ,  C07D213/78 ,  C07D213/81

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, X, m, R2, Y, R3, Z, n, R4, A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.